Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    NOT (aplastic OR fanconi OR blackfan OR sickle OR telangiectasia) | Open Studies | Interventional Studies | anemia | Turkey
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis
Condition: Anemia
Interventions: Drug: Roxadustat;   Drug: Placebo
2 Recruiting Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
Condition: Anemia in Chronic Kidney Disease in Non-dialysis Patients
Interventions: Drug: Roxadustat;   Drug: Placebo
3 Recruiting A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: Luspatercept;   Other: Placebo
4 Recruiting Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload
Condition: Transfusion-dependent Anemia
Interventions: Drug: Deferasirox granule formulation;   Drug: Deferasirox DT formulation
5 Recruiting An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
Conditions: Erythrocyte Transfusion;   Beta-Thalassemia
Interventions: Drug: Luspatercept;   Other: Placebo
6 Recruiting Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
Condition: Thalassemia Major
Interventions: Biological: S-303 Treated Red Blood Cells (RBCs);   Biological: Conventional, untreated Red Blood Cells

Indicates status has not been verified in more than two years